- Details
- Rashid Sayyid and Zach Klaassen discuss the COSMIC-313 clinical trial, examining the use of cabozantinib, nivolumab, and ipilimumab in renal cell carcinoma treatment. Published in the New England Journal of Medicine, the study focuses on patients with locally advanced or metastatic clear cell carcinoma. The trial, a phase III randomized, double-blind, placebo-controlled study, encompassed approxim...
|
- Details
- Rashid Sayyid and Zach Klaassen analyze an ad hoc analysis from the VISION study, published in the Journal of Nuclear Medicine. The study investigates the agreement between readers in the interpretation of 68Ga-PSMA-11 PET/CT scans to determine patient eligibility for 177Lu-PSMA-617 Radioligand Therapy in the treatment of prostate cancer. They elaborate on the study's methodology, including the re...
|
- Details
- Rashid Sayyid and Zach Klaassen, dissect a publication from the VISION study regarding health-related quality of life and pain outcomes with Lu-PSMA-617+ Standard of Care versus Standard of Care alone in patients with mCRPC. This study, conducted across 84 global centers, reveals that the addition of Lu-PSMA-617 to standard care significantly improved overall survival rates from 11.3 to 15.3 month...
|
- Details
- Rashid Sayyid and Zach Klaassen shed light on the TALAPRO-2 study published in The Lancet. This study evaluated the combination of talazoparib, a potent PARP inhibitor, and enzalutamide in treating men with first-line metastatic castration-resistant prostate cancer (mCRPC). They note the poor prognosis for patients with mCRPC and the need for more effective treatments, especially for those with ho...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a publication examining metastatic prostate cancer outcomes in relation to BRCA2 and ATM mutations. Sayyid highlights that around 20-25% of metastatic prostate cancer patients have homologous recombination repair (HRR) gene mutations which are not uniform and can significantly affect treatment responses. He explains that FDA-approved PARP inhibitors (olapari...
|
- Details
- Rashid Sayyid and Zach Klaassen a paper on the development of a patient-reported outcomes (PROs) measure for radionuclide therapy for prostate cancer, published in the Journal of Nuclear Medicine. They explain the importance of PROs in evaluating the impact of these emerging oncology treatments on patients' quality of life. Highlighting a current gap in the literature, they note that existing PRO...
|
- Details
- In this discussion, Rashid Sayyid and Zach Klaassen discuss the findings of a study investigating the significance of bone biomarkers in the prognosis of men with hormone-sensitive prostate cancer. The study, a subgroup analysis from the SWOG S1216 trial, used blood-based biomarkers of bone turnover as prognostic factors for survival. It also examined the performance of Orteronel, a non-steroidal...
|
- Details
- Rashid Sayyid and Zach Klaassen scrutinize a publication from European Urology comparing the diagnostic accuracy of PSMA PET and traditional imaging modalities in initial staging of intermediate to high-risk prostate cancer. The authors systematically review studies comparing PSMA-PET/CT, MRI, and conventional imaging, noting that PSMA-PET/CT shows higher sensitivity and specificity. They also dis...
|
- Details
- Rashid Sayyid and Zach Klaassen dissect the findings of the EXTEND trial, a phase two randomized study focused on the effects of adding metastasis-directed therapy (MDT) to intermittent hormone therapy for oligometastatic prostate cancer. As per the JAMA Oncology published report, despite evidence supporting systemic therapy intensification for metastatic prostate cancer, the combination of MDT an...
|
- Details
- Rashid Sayyid and Zach Klaassen analyze a study on the prognostic role of 68 Ga-PSMA-11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy. The researchers note that traditional assessment tools, such as the Prostate Cancer Working Group 3 criteria, often rely on conventional imaging, limiting the ability to differentiate between responders and those with stable di...
|